Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1997-04-01 (29 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LIEPVRE (68660), Haut-Rhin
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL CATHY WALTER PHARMACIE VAL D ARGENT : revenue, balance sheet and financial ratios
EURL CATHY WALTER PHARMACIE VAL D ARGENT is a French company
founded 29 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LIEPVRE (68660),
this company of category PME
shows in 2016 a revenue of 1.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL CATHY WALTER PHARMACIE VAL D ARGENT (SIREN 412135154)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
1 346 236 €
Net income
116 301 €
66 296 €
95 992 €
143 818 €
127 005 €
100 274 €
100 501 €
97 308 €
118 125 €
131 031 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
134 073 €
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
9.7%
Revenue and income statement
In 2025, EURL CATHY WALTER PHARMACIE VAL D ARGENT generates positive net income of 116 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 131 k€ -> 116 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
116 301 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 76%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.033%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
76.332%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution EURL CATHY WALTER PHARMACIE VAL D ARGENT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
0.291
0.136
3.964
4.385
4.208
3.859
0.774
0.0
0.05
0.033
Financial autonomy
86.394
85.193
81.084
79.831
80.597
82.163
84.056
81.505
75.445
76.332
Repayment capacity
0.017
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
9.905%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
0.032025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of EURL CATHY WALTER PHARMAC... (0.03) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
76.33%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent
In 2025, the financial autonomy of EURL CATHY WALTER PHARMAC... (76.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 135.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
135.7
Liquidity indicators evolution EURL CATHY WALTER PHARMACIE VAL D ARGENT
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
212.63
191.04
187.869
173.225
169.804
194.015
175.235
130.692
112.099
135.7
Interest coverage
0.0
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
135.72025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average
In 2025, the liquidity ratio of EURL CATHY WALTER PHARMAC... (135.70) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL CATHY WALTER PHARMACIE VAL D ARGENT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
61 025 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
17
0
0
0
0
0
0
0
0
0
Customer payment term (days)
4
0
0
0
0
0
0
0
0
0
Supplier payment term (days)
32
0
0
0
0
0
0
0
0
0
Positioning of EURL CATHY WALTER PHARMACIE VAL D ARGENT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of EURL CATHY WALTER PHARMACIE VAL D ARGENT is estimated at
1 847 455 €
(range 1 253 691€ - 2 898 911€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1253k€1847k€2898k€
1 847 455 €Range: 1 253 691€ - 2 898 911€
NAF 5 année 2025
Valuation method used
Net Income Multiple
116 301 €
×
15.9x
=1 847 455 €
Range: 1 253 692€ - 2 898 912€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL CATHY WALTER PHARMACIE VAL D ARGENT with other companies in the same sector:
Frequently asked questions about EURL CATHY WALTER PHARMACIE VAL D ARGENT
What is the revenue of EURL CATHY WALTER PHARMACIE VAL D ARGENT ?
The revenue of EURL CATHY WALTER PHARMACIE VAL D ARGENT in 2016 is 1.3 M€.
Is EURL CATHY WALTER PHARMACIE VAL D ARGENT profitable?
Yes, EURL CATHY WALTER PHARMACIE VAL D ARGENT generated a net profit of 116 k€ in 2025.
Where is the headquarters of EURL CATHY WALTER PHARMACIE VAL D ARGENT ?
The headquarters of EURL CATHY WALTER PHARMACIE VAL D ARGENT is located in LIEPVRE (68660), in the department Haut-Rhin.
Where to find the tax return of EURL CATHY WALTER PHARMACIE VAL D ARGENT ?
The tax return of EURL CATHY WALTER PHARMACIE VAL D ARGENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL CATHY WALTER PHARMACIE VAL D ARGENT operate?
EURL CATHY WALTER PHARMACIE VAL D ARGENT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart